

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

CENTRE FOR HEALTH TECHNOLOGY EVALUATION

Technology Appraisals

**Consultation on Batch 48 draft remits and draft scopes and
summary of comments and discussions at scoping workshops**

Item	Topic ID	Topic title
5.1	952	Aflibercept for treating myopic choroidal neovascularisation
5.2	821	Anamorelin for treating cachexia and anorexia in people with non-small-cell lung cancer
5.3	946	Cenegermin for treating neurotrophic keratitis

Provisional Title	Aflibercept for treating myopic choroidal neovascularisation		
Topic Selection ID Number	8101	Wave / Round	R168
TA ID Number	952		
Company	Bayer		
Anticipated licensing information	Aflibercept has a marketing authorisation in the UK “for adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV).” (issued October 2015).		
Draft remit	To appraise the clinical and cost effectiveness of aflibercept within its marketing authorisation for treating myopic choroidal neovascularisation.		
Main points from consultation	<p>No scoping workshop held.</p> <p>Following the consultation exercise, the Institute is of the opinion that an appraisal of aflibercept for treating myopic choroidal neovascularisation is appropriate.</p> <p>The proposed remit is appropriate. No changes are required.</p>		
Population size	<p>Approximately 3200 people in England have myopic CNV and approximately 1700 people (or 1800 eyes) would be treated per annum.</p> <p>Based on NICE TA298 (Ranibizumab for treating choroidal neovascularisation associated with pathological myopia) costing statement where estimates were approximated using population of England from ONS, published prevalence data and assumption.</p>		
Process (HTA/HST)	Health Technology Appraisal		
Proposed changes to remit (in bold)	None		
Costing implications of remit change	<p>The estimated number of people eligible to be treated per year for this condition is around 1,700, with around 100 people needing bilateral treatment. Therefore the number of eyes needing treatment is around 1,800.</p> <p>The list price of aflibercept is £816 per injection. The treatment is administered by intravitreal injection which costs £107 per administration (2015-16 enhanced tariff option HRG BZ23Z). The number of treatments is not known, however using the follow up treatment schedule from the trial data in the briefing note, the maximum cost per year per eye is estimated to be around £10,000, or around £18 million in England.</p> <p>The company has agreed a patient access scheme with the Department of Health. This scheme provides a simple discount to the list price of aflibercept, with the discount applied at the point of purchase or invoice. The level of the discount is commercial in confidence.</p>		

Timeliness statement	Considering that aflibercept has already received a marketing authorisation for this indication, publication of timely guidance will not be possible.
-----------------------------	---

Provisional Title	Anamorelin for treating cachexia and anorexia in people with non-small cell lung cancer		
Topic Selection ID Number	7200	Wave / Round	R92
TA ID Number	821		
Company	Helsinn (international) and Chugai Pharma (UK)		
Anticipated licensing information	*** Commercial in confidence text removed***		
Draft remit	To appraise the clinical and cost effectiveness of anamorelin within its marketing authorisation for treating anorexia and cachexia associated with non-small cell lung cancer.		
Main points from consultation	<p>Following the consultation exercise and the scoping workshop, the Institute is of the opinion that an appraisal of anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer is <u>appropriate</u>.</p> <p>The proposed remit is not appropriate and should be amended as follows: ‘To appraise the clinical and cost effectiveness of anamorelin within its marketing authorisation for treating cachexia, anorexia or unintended weight loss in people with non-small-cell lung cancer’.</p> <p>This has been updated in line with the anticipated marketing authorisation.</p>		
Population size	<p>Approximately 16,348 people in England would be eligible for treatment with this technology.</p> <p>This estimate is based on 30,000 people being diagnosed with NSCLC per year, of whom approximately 61% of people develop cachexia (18,300).</p>		
Process (HTA/HST)	Health Technology Appraisal		
Proposed changes to remit (in bold)	To appraise the clinical and cost effectiveness of anamorelin within its marketing authorisation for treating cachexia, anorexia or unintended weight loss in people with non-small cell lung cancer.		
Costing implications of remit change	<p>There are approximately 37,000 new diagnoses of lung cancer each year in England. Of these around 80% (30,000) are non-small cell lung cancers (NSCLC). Cancer anorexia-cachexia occurs in approximately 61% of NSCLC and so the estimated population eligible for anamorelin is 18,300.</p> <p>The cost of anamorelin is not yet known though it would represent additional costs to the NHS because it is a new class of drug. If patient health and quality of life is increased there may be reduction in use of existing services and health and social care costs.</p>		
Timeliness statement	Assuming that the anticipated date of the marketing authorisation is the latest date that we are aware of and the expected referral date of this topic, issuing timely guidance for this technology will be possible.		

Provisional Title	Cenegermin for treating neurotrophic keratitis		
Topic Selection ID Number	8033	Wave / Round	R164
TA ID Number	946		
Company	Dompé		
Anticipated licensing information	*** Commercial in confidence text removed***		
Draft remit	To appraise the clinical and cost effectiveness of recombinant human nerve growth factor (rhNGF) within its marketing authorisation for treating neurotrophic keratitis		
Main points from consultation	<p>Following the consultation exercise and the scoping workshop, the Institute is of the opinion that an appraisal of cenegermin for treating neurotrophic keratitis is <u>appropriate</u>.</p> <p>The proposed remit is not appropriate and should be amended as follows:</p> <p>“To appraise the clinical and cost effectiveness of cenegermin within its marketing authorisation for treating neurotrophic keratitis.”</p> <p>This has been updated to reflect the updated non-proprietary name of the technology.</p>		
Population size	<p>Fewer than 6800 people in England would be eligible for treatment with cenegermin.</p> <p>Estimated prevalence of neurotrophic keratitis is 1.6–4.2 per 10,000, of whom about one-third have stage 2 or 3 disease.</p>		
Process (HTA/HST)	Health Technology Appraisal		
Proposed changes to remit (in bold)	To appraise the clinical and cost effectiveness of cenegermin recombinant human nerve growth factor (rhNGF) within its marketing authorisation for treating neurotrophic keratitis		
Costing implications of remit change	<p>Neurotrophic Keratitis is classified as an orphan disease with an estimated prevalence of less than 5 per 10,000 population worldwide. It is estimated that fewer than 6800 people in England would be eligible for treatment with cenegermin.</p> <p>The cost of cenegermin is currently unknown but any cost impact may be off-set against potential reductions in services including follow up appointments and surgery and alternative treatments avoided.</p>		
Timeliness statement	Assuming that the anticipated date of the marketing authorisation is the latest date that we are aware of and the expected referral date of this topic, issuing timely guidance for this technology will be possible.		